The stock has climbed in the double-digits in recent years. Vertex Pharmaceuticals ( VRTX 1.53%) has proven itself to be an ...
Therapeutics Market Size accelerated to USD 10.60 billion in 2024, up from USD 9.22 billion in 2023, and is now projected to expand aggressively to USD 35.09 billion by 2033, recording a CAGR of 14.2% ...
Researchers have found in a new study that triple CFTR modulator therapy, or elexacaftor/tezacaftor/ivacaftor (ETI), produces ...
Sionna Therapeutics, Inc. has announced the presentation of promising preclinical data at the 48th European Cystic Fibrosis Conference in Milan, showing that its nucleotide-binding domain 1 (NBD1) ...
Please provide your email address to receive an email when new articles are posted on . Triple therapy improved lung function, BMI and other factors. Patients naïve to cystic fibrosis transmembrane ...
Please provide your email address to receive an email when new articles are posted on . Patients from minority racial and ethnic groups with cystic fibrosis are less likely to be eligible for cystic ...
- ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR gene ...
Zacks Investment Research on MSN
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
Shares of Arcturus Therapeutics ARCT have plunged 59.4% in the past three months. The massive stock price drop was primarily ...
Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently.
Sionna Therapeutics, Inc. announced that preclinical data on its novel cystic fibrosis (CF) treatment candidates, SION-451 and SION-719, will be presented at the European Cystic Fibrosis Society’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback